Komunikaty firm · 16.10.2026

UCB Announces U.S. FDA Approval for ZILBRYSQ Autoinjector Self-Administration for Adults Living with Generalized Myasthenia Gravis

UCB has secured U.S. FDA approval for ZILBRYSQ, a self-administered once-daily, subcutaneous autoinjector for adults with generalized myasthenia gravis, marking the first macrocyclic peptide C5 inhibitor to receive such approval.